We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cizzle Biotechnology Holdings Plc | LSE:CIZ | London | Ordinary Share | GB00BNG2VN02 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.80 | 1.70 | 1.90 | 1.80 | 1.80 | 1.80 | 14,853 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -1.72M | -0.0043 | -4.19 | 7.14M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/10/2024 08:50 | FFS Joe just sell up. | jambam | |
16/10/2024 08:41 | Or maybe not! | joeb12 | |
09/10/2024 17:12 | Expecting an RNS any day now regarding the MOU finalisation with Cizzle BIO. British Bulls pointing to a bullish resurgence. | joeb12 | |
03/10/2024 14:16 | How is it good ? | joeb12 | |
03/10/2024 14:16 | How is it good ? | joeb12 | |
03/10/2024 12:23 | 3 October 2024 Cizzle Biotechnology Holdings plc ("Cizzle", "Cizzle Biotechnology", or the "Company") Further Update on Strategic Licensing and Partnership Agreement for North America Cizzle Biotechnology, the UK based diagnostics developer, today provides a further update on progress with the Company's planned strategic and exclusive licensing partner in the USA, Cizzle Bio Inc ("BIO"). Following the Company's signing of a memorandum of understanding ("MoU") with BIO announced on 2 April 2024 and the 60 day extension to finalise a full and binding license agreement (the "Agreement") announced on 25 July 2024, the Company has continued to support BIO's plans to market the Company's CIZ1B biomarker and to complete the Agreement. The final details of the Agreement are expected to be completed shortly, at which time the Company will make a further announcement. In the meantime, BIO continues to attract significant clinical interest to build on the recent collaboration with Moffitt Cancer Center, the number one cancer hospital in Florida and the Southeast USA, to test patients with suspicious lung nodules, as announced on 9 September 2024. Enquiries: | tomboyb | |
03/10/2024 12:22 | Good RNS - | tomboyb | |
09/9/2024 10:33 | the usual spike has been and gone! missed it! | abbynat | |
25/7/2024 06:05 | hTTps://www.londonst | dplewis1 | |
18/7/2024 06:05 | Commercialisation.. hTTps://www.londonst | dplewis1 | |
09/7/2024 14:42 | TY Ged, MB - Strategic Advisor at Fluechem in York, with that City being the connection | contact2fsnetcouk | |
09/7/2024 13:55 | I assumed it would be an American company but you could be right | dplewis1 | |
09/7/2024 12:21 | Company up in Aberdeen according to Companies House. Looks like Matt Bower and his wife are the directors. Little bit here about Matt Bower on Linkedin:- | ged5 | |
09/7/2024 11:57 | Market has taken the news positively.. I can't find anything on this Makobo consultancy they've hired though | dplewis1 | |
17/6/2024 08:31 | Sone funds transferring to APH (alliance Pharma) | blackhorse23 | |
17/6/2024 07:20 | Looks like a pretty good update to me. Now timescales in place for FDA etc so hopefully won't continue have the big nervy gaps in comms that we've seen previously | dplewis1 | |
13/6/2024 15:57 | Maybe Penny knows?, or has she also sold. | thehitman1 | |
13/6/2024 13:33 | Jibber, you are invested here, are you saying, you don't know what they are doing?. | thehitman1 | |
12/6/2024 21:19 | Can someone remind me please, does this company actually do anything? | jibba jabber | |
25/5/2024 15:46 | What you meant to say was that you couldn't be a r s e d doing even the very basic research. Had you done so, you would have realised that they did a placing 2mths ago, followed 1mth later by a $100k payment from our potential partners.Once again, had you done so, you wouldn't have looked like the complete idiot that you now do after your lazy attempt at a deramp. Enjoy your weekend. | secretsqu |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions